A California overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
29.1% of California adults have obesity, according to the CDC's 2024 BRFSS prevalence estimates 1. That sits below the national adult rate of 33.1% 1, and it still describes roughly 8,950,108 people once that prevalence is applied to the state's 39,431,263 residents 2 — a figure we model from those two published numbers, not a headcount either agency publishes.
The number that moved in California this year was not the prevalence. It was the coverage. Californians who filled a GLP-1 prescription for weight loss in 2025 cannot fill it under the same benefit in 2026, and many of them found out at the pharmacy counter without an explanation. That is the part of this page worth reading closely.
The honest answer is also the selling point: nothing about our price is Californian.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
Quoting a patient in Sacramento the same number we quote everywhere else is deliberate. A price that moves with a ZIP code is a price engineered around what a market will tolerate, and California is a market that gets tested that way constantly. We would rather publish one number and defend it.
Medi-Cal eliminated coverage of GLP-1 medications for weight loss effective January 1, 2026. Wegovy, Zepbound, and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for weight-management use 3. Coverage continues for type 2 diabetes: a member with a diabetes diagnosis can still be dispensed a GLP-1 through the benefit, while a member whose only indication is obesity cannot 3.
If you were on a Medi-Cal-covered GLP-1 for weight last year, your denial this year is a formulary change, not a judgement about your chart. California moved in the same direction as most of the country here rather than against it, and KFF's tracking of state Medicaid GLP-1 policy is the clearest public record of that retreat 4.
Commercial coverage in California is a separate question, and your employer decides it more than the state does. Two people working at two San Francisco employers, insured through the same carrier, can get opposite answers, because weight-management drug coverage is a benefit the employer elects or declines.
What to do next depends on which bucket you are in. If you have commercial coverage, pull the drug list for your plan year and search it for Wegovy, Zepbound, and the phrase "weight management"; if the drugs appear, ask the plan for its prior-authorization criteria, which in California commonly involve a documented BMI threshold and evidence of supervised treatment. If they are excluded, or if you are a Medi-Cal member whose only indication is weight, your realistic options are a documented comorbidity appeal, a manufacturer direct-pay program for the branded drug, or a cash-pay physician-supervised program such as Astra's.
Yes. California law allows licensed providers to prescribe non-controlled medications such as semaglutide and tirzepatide through telehealth: under Business and Professions Code section 2242 5, the required prior examination does not have to be in-person or even a real-time video visit, so long as the provider meets the same standard of care that applies to in-person care, as the Medical Board of California requires. Providers treating California patients must hold a California medical license, and patients must be informed about and consent to telehealth before care begins (section 2290.5) 6. Rules for compounded medications are set separately — by federal law (FDA Section 503A) and by the California State Board of Pharmacy 7, whose updated compounding regulations took effect October 1, 2025 — and those rules have continued to change through 2025 and 2026. Astra visits are conducted by licensed providers, and prescriptions are filled by licensed pharmacies.
Our provider group holds California licensure and our partner pharmacies are licensed to dispense into the state, so a resident of the Central Valley or the Inland Empire can complete an intake, be evaluated, and receive medication at a California address without driving to a metro clinic.
Astra treats patients in California through state-licensed physicians.
City pages carry local access context — county figures, clinician supply, and what the local market charges — with the same sourcing rules as this page.
Not for weight loss. Effective January 1, 2026, Medi-Cal removed Wegovy, Zepbound, and Saxenda from the Contract Drugs List for weight-management indications. GLP-1 medications remain covered for type 2 diabetes indications.
No, and that is deliberate. Astra charges one price in every state it serves, published once in the cost section above. There is no California price list, no regional surcharge, and no local discount.
No. Under Business and Professions Code section 2242, the prior examination required before prescribing does not have to happen in person or by real-time video, provided the licensed provider meets the same standard of care as in-person treatment. The provider must hold a California license, and you must be informed about and consent to telehealth before care begins under section 2290.5.
Compounded semaglutide is available in California only when federal and state compounding conditions are met for you individually. Since the FDA declared the semaglutide shortage resolved in February 2025 and ended its related enforcement flexibility in spring 2025, a compounding pharmacy generally may dispense a compounded version of a commercially available GLP-1 only for an individual patient with a documented, clinically significant difference from the FDA-approved product — and California's Board of Pharmacy regulations (effective October 1, 2025) go further than federal law, requiring the pharmacist to independently verify and document that difference in addition to the prescriber's determination. Whether a compounded medication is appropriate for you is a decision for a licensed provider, and availability can change as rules evolve.
Tell your care team your new address before your next refill. A prescription is tied to the state where you are located when you are treated, so a licensed provider in your new state has to take over your care, and your pharmacy has to be licensed to dispense there. If Astra serves your new state, we transfer the plan without restarting it; if we do not, we say so and stop billing rather than shipping into a state we are not licensed in.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.